BIRC5 and Miyoshi myopathy: Targeting the miR-101-3p/survivin axis in MM by either the overexpression of miR-101-3p or by the silencing of survivin induces apoptosis even in the presence of BMSCs, thus overcoming the microenvironment-induced drug resistance [118].